Liquid *versus* tablet levo-thyroxine (L-T4) formulation in *de novo* treatment of hypothyroidism in patients with Hashimoto’s thyroiditis: tolerability and changes in quality of life (QoL).

Marilena Sidoti (1), Massimo Giusti (1, 2) Centro Diagnostico “Priamar”, Savona (1) and Dipartimento di Medicina Interna (2), Università di Genova, Genoa, Italy.

**AIM**
The aim of this work was to evaluate effectiveness, tolerability and QoL changes in Hashimoto’s thyroiditis (HT) patients who begin de novo L-T4 treatment for sub clinical or overt hypothyroidism.

**Methods**
At randomization sex distribution (85% females), median age (59 yrs), TSH (TA 11.0±2.5 mIU/L; SO 21.5±8.5 mIU/L) and thyroid hormones, thyroid volume (8 ml), blood pressure, heart rate but not BMI (TA 26.7±1.3 kg/m2, LI 22.7±0.8 kg/m2; P=0.02) was similar between groups. Hypothyroid symptoms are scored with Billewicz scale (BS), subjective satisfaction and QoL were evaluated with a visual analogic scale (VAS) and the ThyPRO inventory. In both groups of patients the L-T4 treatment (IBSA Farmaceutici), was begun a the dosages of 50 µg/day. Data are reported as mean ± SEM.

**Conclusion**
A protocol in a non-public setting is burdened by a elevated number of drop-out and the number of data available can be a limitation of this study. However both liquid and tablet L-T4 formulations are similar in effectiveness but dosages need to be carefully increased when de novo started for the control of hypothyroidism. The tolerability of LI or TA L-T4 is similar and QoL improves in all patients on therapy.